#United States #New York #Pomerantz LLP #Harmony Biosciences #FDA Decision

Pomerantz Law Firm Investigates Harmony Biosciences Holdings

Background

The Pomerantz Law Firm has initiated an investigation into potential claims on behalf of investors in Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY). This investigation comes in the wake of serious concerns regarding possible securities fraud and other illegal business activities linked to its leadership.

Recent Developments

On February 19, 2025, Harmony Biosciences faced a significant setback when it announced that it had received a Refusal to File (RTF) letter regarding its product, pitolisant, intended for the treatment of excessive daytime sleepiness (EDS) in adults with idiopathic hypersomnia (IH). The company's announcement revealed that the treatment did not meet the necessary statistical significance when compared to a placebo in its phase three INTUNE study. Following this negative news, the company’s stock price decreased by nearly 10%, shedding $3.77 per share and closing at $35.32.

Implications for Investors

Investors who bought shares prior to this announcement may have grounds for legal action if they believe they were misled by Harmony or its executive team. Pomerantz LLP encourages affected investors to reach out for insights on how they can join the investigation. The firm is committed to seeking justice for those impacted by potential misconduct in the corporate environment.

About Pomerantz LLP

Pomerantz LLP, established more than 85 years ago, is widely recognized as a leader in the field of securities class action litigation. Founded by Abraham L. Pomerantz, often revered as the father of class action lawsuits, the firm has a proven track record of fighting for the rights of investors. With offices across major cities including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, Pomerantz continues to advocate for clients who have fallen victim to securities fraud and breaches of fiduciary duty. The firm has successfully secured substantial settlements for its clients in many high-profile cases, reinforcing its reputation in the legal community. More information is available on their website at www.pomlaw.com.

Conclusion

This investigation is a crucial step for investors looking to protect their interests in the wake of Harmony Biosciences' recent troubles. As the situation unfolds, those affected by the company's alleged misbehavior are encouraged to seek guidance and explore their options for legal recourse. Pomerantz LLP promises to uphold the rights of investors, striving for accountability in the corporate world.

For additional information regarding the investigation, investors can contact Danielle Peyton at Pomerantz LLP via email or phone.

Contact:
Danielle Peyton
Pomerantz LLP
Email: [email protected]
Phone: 646-581-9980 ext. 7980